Augurex Life Sciences Corp.

About

Augurex is a biotechnology company that is focused on the development of biomarkers, which are substances in the body that inform patient conditions to assist in their diagnosis and to help optimize therapy selection and patient management. Extracellular 14-3-3η protein represents the company’s first biomarker and also serves as a drug target for the potential treatment of rheumatoid arthritis (RA), a particularly debilitative form of arthritis. By commercializing a biomarker for arthritis, Augurex is enabling a personalized medicine application for a potentially much larger commercial market and shareholder exit.